AAdd image
Adipotide
Weight LossSingleAlso known as: FTPP
A proapoptotic peptidomimetic designed to selectively target adipose-tissue vasculature, originally studied in primate weight-loss models.
Half-life
—
Common dose
0.4 – 0.5 mg
Dosing frequency
Daily
Administration
Subcutaneous
How it works
Adipotide targets prohibitin on white-adipose endothelial cells, triggering apoptosis of fat-tissue blood supply and causing rapid fat loss in animal studies.
Protocol notes
No established human-use protocols. Preclinical primate work used 0.43 mg/kg daily for 4 weeks. Significant safety concerns limit human use.
Reported side effects
Kidney toxicity, dehydration, electrolyte disturbance. Not recommended for human use without clinical oversight.